ReviewTranslational oncology2026
Exploiting cellular senescence in hematologic malignancies.
Review in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular Senescence is characterized by stable cell cycle arrest and major changes in cell morphology and physiology. Accumulating evidence indicates that senescence-associated phenotypic alterations in blood cells drive the initiation and progression of hematologic malignancies. Therefore, we reviewed the phenotypes associated with cellular senescence and the regulatory mechanisms of cellular senescence in hematological malignancies. Notably, chemical induction of cellular senescence and selectively elimination of senescent cells can effectively inhibit tumor cell proliferation and enhance the efficacy of chemotherapy. This review also discusses the role of cellular senescence in the treatment of hematological malignancies, providing an in-depth understanding of the role of cellular senescence as a double-edged sword in cancer biology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.